MYM and Sublime Sign Consulting Agreement With Master Breeder Sasha Przytyk

Thursday, January 18, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

VANCOUVER, British Columbia, Jan. 18, 2018 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (OTC:

MYMMF) (the "Company" or "MYM") is pleased to announce that it and its subsidiary, Sublime Culture Inc., have entered into a consulting agreement with Sasha Przytyk, who will act as Master Breeder at the Sublime
facility in Laval, Québec. 

As Master Breeder, Mr. Przytyk will be responsible for developing a comprehensive Cannabis seed breeding and production program for Sublime Culture and MYM. His initial focus will be to search out and select source seed varieties from breeders and reputable international seed houses. In parallel, Sasha will design and conduct an ongoing research program, to evaluate and analyze seed strains under varying conditions. In the long term, Sasha promises to create improved, proprietary varieties through selection and hybridization, to supply the Canadian and international cannabis seed market.

Sasha has extensive experience in the medicinal cannabis and horticultural sector. He is a designated cannabis grower, licensed through Health Canada's MMAR and AMCPR programs since 2009. Sasha was the first private recipient of a Health Canada Industrial Hemp Research license in Québec. He is currently the owner of a cannabis seed brand-management company, Shazam Farms International Inc.

Sasha has extensive experience as a guest speaker and delegate at international cannabis conferences and symposiums. He is also an accomplished publisher in the field, writing numerous articles on hemp and its cultivation.

Sasha established 'The Joint Doctor' and 'High-Bred Seeds' as world-renowned seed brands. Through the revolutionary strain 'Lowryder,' he introduced the concept of autoflowering cannabis. Lowryder is recognized worldwide as the first 100% autoflowering variety and The Joint Doctor has been dubbed the 'Father of Autoflowering.' Widely adopted by seed companies today, autoflowering strains now represent approximately 40% of the European seed market.

"We are thrilled to welcome Sasha to the MYM team as Master Breeder. His experience in the hemp, cannabis, and horticultural industry is unparalleled," said Rob Gietl, MYM's CEO. "Sasha's innovation in seed technology will prove to be a valuable asset to the shareholders of MYM as growing cannabis becomes increasingly accepted and adopted around the world."

Pursuant to the five-year consulting agreement, which is with Mr. Przytyk's company, Shazam Farms, Sasha will receive a signing bonus of $25,000, paid in 7,062 MYM common shares at a deemed price per share of $3.54.  

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. MYM is also a partner in a 1.2 million square-foot production project (the Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).

On Behalf of the BoardRob Gietl, CEO MYM Nutraceuticals

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States.The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any state securities law and may not be offered or sold in the 'United States', as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations Terry Brown +1-855-696-2261

Keep up-to-date with MYM on our social media channels: Twitter: @MYM_Nutra Facebook: @mymcanada Instagram: @MYM_Nutra

Cision View original content:

SOURCE MYM Nutraceuticals Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store